W. R. Bishop

发表

An analysis of time distribution and work load in the area of individual tactical development

Ronald A. Weitzman, James O. McGranahan, W. R. Bishop, 1983 .

Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression

Luquan Wang, Beth Hutchins, Ferdous Gheyas, 2003, Oncogene.

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Shuxia Zhao, Leigh Zawel, Stephen Fawell, 2013, Cancer discovery.

Identification and characterization of zinc binding sites in protein kinase C.

W. R. Bishop, S. Hubbard, W. Hendrickson, 1991, Science.

Farnesyl Transferase Inhibitors: Mechanism of Action, Translational Studies and Clinical Evaluation

W. R. Bishop, C. Baum, P. Kirschmeier, 2003, Cancer biology & therapy.

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

W. R. Bishop, E. Maxwell, Marnie McGuirk, 2001, Experimental cell research.

Tricyclic Farnesyl Protein Transferase Inhibitors: Antitumor Activity and Effects on Protein Prenylation

W. R. Bishop, P. Kirschmeier, L. Armstrong, 2000 .

Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice

Walter A. Korfmacher, W. R. Bishop, Jianping Chen, 1999, Cancer Chemotherapy and Pharmacology.

Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.

W. R. Bishop, D. V. Von Hoff, T. Petit, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel tricyclic aminoacetyl and sulfonamide inhibitors of Ras farnesyl protein transferase

W. R. Bishop, R. Doll, F. G. Njoroge, 1996 .

SCH 58450, a novel farnesyl protein transferase inhibitor possessing a 6a,12a:7,12-diepoxybenz[a]anthracene ring system

W. R. Bishop, R. Patton, Mahesh Patel, 1995 .

Novel Tricyclic Inhibitors of Farnesyl Protein Transferase

W. R. Bishop, P. Kirschmeier, J. Schwartz, 1995, The Journal of Biological Chemistry.

Farnesyl Transferase Inhibitors: From Targeted Cancer Therapeutic to a Potential Treatment for Progeria

W. R. Bishop, P. Kirschmeier, R. Doll, 2011 .

Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.

W. R. Bishop, T. Tauchi, K. Ohyashiki, 2003, Molecular cancer therapeutics.

Treatment of neoplastic meningitis with intrathecal temozolomide.

W. R. Bishop, R. McLendon, A. Friedman, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.

W. R. Bishop, J. English, P. Kirschmeier, 2002, Experimental cell research.

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.

W. R. Bishop, G. Daley, P. Kirschmeier, 2001, Blood.

Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras- and sis-transformed normal rat kidney cells.

W. R. Bishop, R. Stein, J. Preiss, 1986, The Journal of biological chemistry.

Enzymatic quantification of sphingosine in the picomole range in cultured cells.

W. R. Bishop, R. Bell, P. V. Van Veldhoven, 1989, Analytical biochemistry.

Procédés de traitement ou de prévention de cancer colorectal

W. R. Bishop, Yaolin Wang, Yan Wang, 2009 .

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors

Edward S. Kim, W. R. Bishop, P. Thall, 2004, Clinical Cancer Research.

Efficacy of SCH 66336 , a Farnesyl Transferase Inhibitor , in Conjunction with Imatinib against BCR-ABL-positive Cells 1

W. R. Bishop, T. Tauchi, K. Ohyashiki, 2003 .

Analogs of 4-(3-bromo-8-methyl-10-methoxy-6,11-dihydro-5H-benzo[5,6]-cyclo hepta[1,2-b]pyridin-11-yl)-1-(4-pyridinylacetyl)piperidine N-oxide as inhibitors of farnesyl protein transferase.

W. R. Bishop, J. Weinstein, L. James, 1999, Bioorganic & medicinal chemistry letters.

Inhibitors of farnesyl protein transferase. Synthesis and biological activity of amide and cyanoguanidine derivatives containing a 5,11-dihydro[1]benzthiepin, benzoxepin, and benzazepin [4,3-b]pyridine ring system.

W. R. Bishop, P. Kirschmeier, J. Weinstein, 1998, Bioorganic & medicinal chemistry letters.

A cembranolide diterpene farnesyl protein transferase inhibitor from the marine soft coral Lobophytum cristagalli

W. R. Bishop, A. McPhail, R. Patton, 1996 .

SCH 47112, a novel staurosporine derivative, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and epidermal hyperplasia in hairless mouse skin

W. R. Bishop, N. Reynolds, G. Fisher, 1997, Archives of Dermatological Research.

Regulation of phospholipid hydrolysis and second messenger formation by protein kinase C.

W. R. Bishop, J. Pachter, J. Pai, 1992, Advances in enzyme regulation.

Characterization of site-specific mutants altered at protein kinase C beta 1 isozyme autophosphorylation sites.

W. R. Bishop, L. Wang, J. Zhang, 1993, Proceedings of the National Academy of Sciences of the United States of America.

In vivo prenylation analysis of Ras and Rho proteins.

W. R. Bishop, D. Whyte, P. Kirschmeier, 2001, Methods in enzymology.

Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models.

W. R. Bishop, P. Kirschmeier, L. Nielsen, 2001, Methods in enzymology.

Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation.

W. R. Bishop, M. Snow, P. Kirschmeier, 1997, Bioorganic & medicinal chemistry.

chronic myeloid leukemia BCR/ABL-induced murine leukemia and primary cells from patients with Activity of the farnesyl protein transferase inhibitor SCH66336 against

W. R. Bishop, G. Daley, P. Kirschmeier, 2013 .

Protein farnesyltransferase assays.

W. R. Bishop, F. L. Zhang, W. Bishop, 2001, Current protocols in pharmacology.

Attenuation of sn-1,2-diacylglycerol second messengers. Metabolism of exogenous diacylglycerols by human platelets.

W. R. Bishop, R. Bell, W. Bishop, 1986, The Journal of biological chemistry.

A novel class of platelet activating factor antagonists from Phoma sp.

W. R. Bishop, V. Gullo, A. Horan, 1993, The Journal of antibiotics.

Functions of diacylglycerol in glycerolipid metabolism, signal transduction and cellular transformation.

W. R. Bishop, R. Bell, 1988, Oncogene research.

Ceramide quantitation: evaluation of a mixed micellar assay using E. coli diacylglycerol kinase.

W. R. Bishop, R. Bell, P. V. Van Veldhoven, 1995, Biochemistry and molecular biology international.

Attenuation of sn-1,2-diacylglycerol second messengers by diacylglycerol kinase. Inhibition by diacylglycerol analogs in vitro and in human platelets.

W. R. Bishop, R. Bell, B. Ganong, 1986, The Journal of biological chemistry.

Endothelin-1 activates phospholipase D and thymidine incorporation in fibroblasts overexpressing protein kinase C beta 1.

W. R. Bishop, J. Pai, E. Dobek, 1991, Cell regulation.

Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.

W. R. Bishop, F. G. Njoroge, C. Strickland, 2003, Bioorganic & medicinal chemistry.

Phosphorylation of Thr642 is an early event in the processing of newly synthesized protein kinase C beta 1 and is essential for its activation.

W. R. Bishop, J. Schwartz, J. Zhang, 1994, The Journal of biological chemistry.

Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.

W. R. Bishop, P. Kirschmeier, R. Doll, 1999, Journal of medicinal chemistry.

Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta [1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase.

W. R. Bishop, T. Guzi, A. Nomeir, 1999, Bioorganic & medicinal chemistry.

Synthesis of isomeric 3-piperidinyl and 3-pyrrolidinyl benzo[5,6]cyclohepta[1,2-b]pyridines: sulfonamido derivatives as inhibitors of Ras prenylation.

W. R. Bishop, A. McPhail, L. James, 1998, Bioorganic & medicinal chemistry.

Farnesyltransferase inhibitors as anticancer agents: critical crossroads.

W. R. Bishop, P. Kirschmeier, R. Doll, 2004, Current opinion in drug discovery & development.

Usnic acid amide, a phytotoxin and antifungal agent from Cercosporidium henningsii

W. R. Bishop, D. Loebenberg, G. Strobel, 1992 .

Assembly of the endoplasmic reticulum phospholipid bilayer: the phosphatidylcholine transporter

W. R. Bishop, R. Bell, W. Bishop, 1985, Cell.

Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005.

W. R. Bishop, P. Kirschmeier, A. Basso, 2006, Journal of Lipid Research.

Indolocarbazole nitrogens linked by three-atom bridges: a potent new class of PKC inhibitors

W. R. Bishop, A. Ganguly, S. Vice, 1994 .

Assembly of phospholipids into cellular membranes: biosynthesis, transmembrane movement and intracellular translocation.

W. R. Bishop, R. Bell, R M Bell, 1988, Annual review of cell biology.

Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy.

W. R. Bishop, Suxing Liu, Ming Liu, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Discovery of C-imidazole azaheptapyridine FPT inhibitors.

W. R. Bishop, P. Kirschmeier, R. Doll, 2010, Bioorganic & medicinal chemistry letters.

The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo

W. R. Bishop, L. Nielsen, G. Hajian, 2000, Cancer Chemotherapy and Pharmacology.

K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*

W. R. Bishop, D. Whyte, P. Kirschmeier, 1997, The Journal of Biological Chemistry.

Enhanced FTase activity achieved via piperazine interaction with catalytic zinc.

W. R. Bishop, A. Nomeir, F. G. Njoroge, 2006, Bioorganic & medicinal chemistry letters.

The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling

W. R. Bishop, A. Mirza, P. Kirschmeier, 2005, Journal of Biological Chemistry.

A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.

W. R. Bishop, J. Sloan, J. Sloan, 2000, Cancer research.

Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity.

W. R. Bishop, R. Doll, A. Nomeir, 1998, Journal of medicinal chemistry.

Biological effects and mechanism of action of farnesyl transferase inhibitors.

W. R. Bishop, P. Kirschmeier, L. Armstrong, 2000, Chemical research in toxicology.

Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules*

W. R. Bishop, P. Kirschmeier, L. Armstrong, 2000, The Journal of Biological Chemistry.

Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance

W. R. Bishop, B. Dasmahapatra, Yaolin Wang, 2004 .

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.

W. R. Bishop, P. Kirschmeier, L. Wang, 1998, Journal of medicinal chemistry.

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

W. R. Bishop, Luquan Wang, Qun Wu, 2002, Oncogene.

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

W. R. Bishop, P. Kirschmeier, B. Long, 2009, International journal of cancer.

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

W. R. Bishop, P. Kirschmeier, Ming Liu, 2008, Gynecologic oncology.

Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.

W. R. Bishop, P. Kirschmeier, F. G. Njoroge, 2004, Bioorganic & medicinal chemistry letters.

Synthesis of 5,6-dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine derivatives as inhibitors of ras farnesyl protein transferase.

W. R. Bishop, P. Weber, P. Kirschmeier, 2002, Bioorganic & medicinal chemistry letters.

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Walter A. Korfmacher, W. R. Bishop, J. Catino, 1998, Cancer research.

Synthesis of (5,6‐Dihydro‐11H‐benzo[5,6]cyclohepta [1,2‐b]pyridin‐11‐ylidene)‐1‐piperidine‐N‐cyanoguanidine Derivatives (I) as Inhibitors of Ras Farnesyl Protein Transferase.

W. R. Bishop, P. Weber, P. Kirschmeier, 2002 .

Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.

Walter A. Korfmacher, W. R. Bishop, J. Chen, 1998, Journal of medicinal chemistry.

Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.

W. R. Bishop, J. Catino, M. Malkowski, 1997, Journal of medicinal chemistry.

Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferase.

W. R. Bishop, N. Carruthers, P. Kirschmeier, 1997, Bioorganic & medicinal chemistry.

Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.

W. R. Bishop, Meilin Liu, L. Nielsen, 1999, Cancer research.

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

W. R. Bishop, L. Presta, Yaolin Wang, 2005, Molecular Cancer Therapeutics.

Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I*

W. R. Bishop, P. Kirschmeier, W. Windsor, 1997, The Journal of Biological Chemistry.

SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

W. R. Bishop, M. Demma, E. Maxwell, 2010, The Journal of Biological Chemistry.

Integrative Genomics Revealed RAI3 Is a Cell Growth-promoting Gene and a Novel P53 Transcriptional Target*

W. R. Bishop, T. Mcclanahan, Qun Wu, 2005, Journal of Biological Chemistry.

Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells.

W. R. Bishop, E. Maxwell, Yan Wang, 2002, Molecular Cancer Therapeutics.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

W. R. Bishop, R. Sullivan, K. Flaherty, 2018, JCI insight.

Differential regulation of phosphoinositide and phosphatidylcholine hydrolysis by protein kinase C-beta 1 overexpression. Effects on stimulation by alpha-thrombin, guanosine 5'-O-(thiotriphosphate), and calcium.

W. R. Bishop, R. Mayer-Ezell, J. Pachter, 1992, The Journal of biological chemistry.

Overexpression of protein kinase C beta 1 enhances phospholipase D activity and diacylglycerol formation in phorbol ester-stimulated rat fibroblasts.

W. R. Bishop, I. Weinstein, J. Pachter, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Lipid posttranslational modifications. Farnesyl transferase inhibitors.

W. R. Bishop, P. Kirschmeier, A. Basso, 2006, Journal of lipid research.

Phospholipid Bilayer Assembly: Facilitated Transmembrane Movement of Phosphatidylcholine

W. R. Bishop, R. Bell, B. Ganong, 1986 .

A farnesyl transferase inhibitor suppresses TPA‐mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse

W. R. Bishop, R. Tennant, J. Haseman, 2000, Molecular carcinogenesis.

Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin.

W. R. Bishop, R. Doll, L. Wang, 1990, Biochemical pharmacology.

A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts

W. R. Bishop, Yaolin Wang, Xiaoying Wang, 2010, Molecular Cancer Therapeutics.

Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity.

W. R. Bishop, P. Kirschmeier, R. Doll, 1999, Bioorganic & Medicinal Chemistry.

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

W. R. Bishop, D. Hicklin, G. Scapin, 2016, ACS medicinal chemistry letters.

Substitution of cadmium for zinc in farnesyl:protein transferase alters its substrate specificity.

W. R. Bishop, P. Casey, H. Fu, 1996, Biochemistry.